Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Adamas Pharmaceuticals (NASDAQ: ADMS) today and set a price target of $70. The company’s shares opened today at $25.63.
Rivkind Koffler commented:
“We provide more details below. The significance of these data are that they provide even more support for Gocovri differentiation from generic forms of amantadine, or other extended release forms that lack similar evidence. The next catalyst for the stock we expect is 2Q:18 earnings. We reiterate our Buy rating and $70 PT.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 13.7% and a 48.8% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Adamas Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $47.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $44 and a one-year low of $13.50. Currently, Adamas Pharmaceuticals has an average volume of 661.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adamas Pharmaceuticals, Inc. is a pharmaceutical company, which engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products includes ADS-5012, ADS-4101, and Namenda XR. The ADS-5102 is a treatment for levodopa-induced dyskinesia in patients with Parkinson’s disease.
